3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Active not recruiting
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Observational
1
Interventional
1
Sponsor
Cancer Type
Genitourinary
2
Conditions
Prostatic Neoplasms
8
Metastatic Castration-resistant Prostate Cancer
2
Prostatic Neoplasms, Castration-Resistant
1
Prostate Adenocarcinoma
1
Metastatic Castrate Resistant Prostate Cancer (mCRPC)
1
Lymphatic Metastasis
1
Hormone Refractory Prostate Cancer
1
Carcinoma, Renal Cell
1
Bone Metastatic Castration-resistant Prostate Cancer
1
Anatomic Stage IV Breast Cancer AJCC v8
1
Interventions
olaparib
4
Pluvicto
4
Abiraterone Acetate
4
Prednisone
3
Prednisolone
3
testosterone 17 beta-cypionate
2
radium Ra 223 dichloride
2
enzalutamide
2
darolutamide
2
Docetaxel
2
Androgen Antagonists
2
sipuleucel-T
1
niraparib
1
lactitol
1
fludarabine phosphate
1
fludarabine
1
fluciclovine F-18
1
enfortumab vedotin
1
cabozantinib
1
cabazitaxel
1
alovudine
1
abiraterone
1
Standard of Care
1
Radium-223
1
PSMA-617
1
Nivolumab
1
Gonadotropin-Releasing Hormone
1
Cyclophosphamide
1
Bortezomib
1
Blood Specimen Collection
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Metastatic Castration-resistant Prostate Cancer
×
radium Ra 223 dichloride
×
1 year
×
Clear all
NCT04109729
2026-06-01
Rad2Nivo
University of Utah
Phase 1
Active not recruiting
39 enrolled
NCT02141438
2025-10-16
REASSURE
Bayer
Completed
1,472 enrolled
18 charts